As a result of the current Federal government funding situation, the information on this website may not be up to date or acted upon.  

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit

Updates regarding government operating status and resumption of normal operations can be found at

NIH Seeks Input on Prioritizing Renewable Affinity Reagents

The National Institutes of Health (NIH) is seeking community input on a priority list for renewable affinity reagents for human transcription factors. For more information or to provide input, please visit,

This outreach effort is part of the Protein Capture Reagents Program. This program was initiated by the NIH Common Fund in response to concerns raised by scientific community regarding the lack of access to well-characterized, analytically validated and affordable renewable protein capture reagents.

This is a pilot program that aims to evaluate if a community resource of high quality, renewable affinity reagents can be economically generated and validated for all human proteins, and to develop technologies that will lead to next generation platforms for producing renewable protein capture reagents. This pilot effort includes the generation of affinity reagents (monoclonal antibodies and recombinant Fabs) against all human transcription factors as a test case.